Jump Financial LLC Invests $128,000 in Immix Biopharma, Inc. (NASDAQ:IMMX)

Jump Financial LLC purchased a new position in shares of Immix Biopharma, Inc. (NASDAQ:IMMXFree Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 18,500 shares of the company’s stock, valued at approximately $128,000. Jump Financial LLC owned about 0.09% of Immix Biopharma as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also modified their holdings of the company. Tocqueville Asset Management L.P. purchased a new stake in shares of Immix Biopharma during the third quarter worth about $41,000. OLD National Bancorp IN purchased a new stake in shares of Immix Biopharma during the fourth quarter worth about $69,000. Commonwealth Equity Services LLC grew its stake in shares of Immix Biopharma by 26.4% during the third quarter. Commonwealth Equity Services LLC now owns 28,855 shares of the company’s stock worth $99,000 after acquiring an additional 6,030 shares during the last quarter. Imprint Wealth LLC grew its stake in shares of Immix Biopharma by 49.4% during the fourth quarter. Imprint Wealth LLC now owns 34,483 shares of the company’s stock worth $239,000 after acquiring an additional 11,400 shares during the last quarter. Finally, Private Advisor Group LLC purchased a new stake in shares of Immix Biopharma during the fourth quarter worth about $690,000. Hedge funds and other institutional investors own 11.26% of the company’s stock.

Immix Biopharma Stock Down 5.6 %

Immix Biopharma stock opened at $2.18 on Thursday. Immix Biopharma, Inc. has a 52 week low of $1.55 and a 52 week high of $7.75. The company has a market capitalization of $57.57 million, a price-to-earnings ratio of -2.34 and a beta of 0.24. The stock has a 50-day moving average price of $2.50 and a 200 day moving average price of $3.83.

Immix Biopharma (NASDAQ:IMMXGet Free Report) last released its earnings results on Thursday, May 9th. The company reported ($0.22) EPS for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.01. Research analysts anticipate that Immix Biopharma, Inc. will post -0.91 EPS for the current fiscal year.

About Immix Biopharma

(Free Report)

Immix Biopharma, Inc, a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease.

Further Reading

Institutional Ownership by Quarter for Immix Biopharma (NASDAQ:IMMX)

Receive News & Ratings for Immix Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immix Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.